FDA-cleared profile

CINA-VCF

Avicenna.AI · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Parallel worklist triage for suspected vertebral compression fractures in patients aged 50 years and over within the standard-of-care bone-health setting; not a diagnostic device

Clinical role
Parallel triage/notification application that flags suspected VCF cases without altering original images or removing cases from the standard worklist
Images and patients
CT/CTA · Thoracic and lumbar vertebrae T1-L5 within chest and/or abdomen CT
Key limitation
Keep in mind: Not intended for diagnosis; preview is informational and not diagnostic; clinician must review the full study using standard of care; the device operates in parallel and does not alter original images or remove cases from the worklist

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Parallel worklist triage for suspected vertebral compression fractures in patients aged 50 years and over within the standard-of-care bone-health setting; not a diagnostic device
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Thoracic and lumbar vertebrae T1-L5 within chest and/or abdomen CT Input: DICOM non-enhanced or contrast-enhanced CT of the chest and/or abdomen in patients aged 50 years and over, including at least three consecutive measurable vertebrae in the T1-L5 portion of the spine
  • Who uses it?Intended users: Hospital networks and appropriately trained medical specialists within the standard-of-care bone-health setting
  • What does the software produce?Output: Worklist icon/flag for suspected VCF at T1-L5 and a compressed grayscale unannotated preview marked not for diagnostic use; results are transferred to PACS or a workstation for prioritization and the full original study remains required
  • What is its most important limitation?Key limitation: Not intended for diagnosis; preview is informational and not diagnostic; clinician must review the full study using standard of care; the device operates in parallel and does not alter original images or remove cases from the worklist

Clinical takeaway. Clinical role: Parallel worklist triage for suspected vertebral compression fractures in patients aged 50 years and over within the standard-of-care bone-health setting; not a diagnostic device

Evidence takeaway. Evidence from the reviewed source record: Retrospective multicenter, multinational, blinded study used 474 cases, 180 positive and 294 negative, with ground truth by consensus of three US-board-certified expert radiologists. Primary endpoint ROC AUC was 0.974 (95% CI 0.962-0.986) against a 0.95 performance goal. Additional sensitivity was 95.2% (90.7%-97.9%), specificity 92.9% (89.4%-96.5%), and accuracy 93.7% (91.1%-95.7%). Mean time-to-notification was 23.4 seconds for all cases and 21.7 seconds for 158 true-positive cases

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Parallel worklist triage for suspected vertebral compression fractures in patients aged 50 years and over within the standard-of-care bone-health setting; not a diagnostic device
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Parallel triage/notification application that flags suspected VCF cases without altering original images or removing cases from the standard worklist
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM non-enhanced or contrast-enhanced CT of the chest and/or abdomen in patients aged 50 years and over, including at least three consecutive measurable vertebrae in the T1-L5 portion of the spine
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Worklist icon/flag for suspected VCF at T1-L5 and a compressed grayscale unannotated preview marked not for diagnostic use; results are transferred to PACS or a workstation for prioritization and the full original study remains required
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Hospital-network radiology workflow in a standard-of-care bone-health setting for patients aged 50 years and over
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Hospital networks and appropriately trained medical specialists within the standard-of-care bone-health setting
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Not intended for diagnosis; preview is informational and not diagnostic; clinician must review the full study using standard of care; the device operates in parallel and does not alter original images or remove cases from the worklist
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
Retrospective multicenter, multinational, blinded study used 474 cases, 180 positive and 294 negative, with ground truth by consensus of three US-board-certified expert radiologists. Primary endpoint ROC AUC was 0.974 (95% CI 0.962-0.986) against a 0.95 performance goal. Additional sensitivity was 95.2% (90.7%-97.9%), specificity 92.9% (89.4%-96.5%), and accuracy 93.7% (91.1%-95.7%). Mean time-to-notification was 23.4 seconds for all cases and 21.7 seconds for 158 true-positive cases
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Retrospective multicenter, multinational, blinded study used 474 cases, 180 positive and 294 negative, with ground truth by consensus of three US-board-certified expert radiologists. Primary endpoint ROC AUC was 0.974 (95% CI 0.962-0.986) against a 0.95 performance goal. Additional sensitivity was 95.2% (90.7%-97.9%), specificity 92.9% (89.4%-96.5%), and accuracy 93.7% (91.1%-95.7%). Mean time-to-notification was 23.4 seconds for all cases and 21.7 seconds for 158 true-positive cases
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
95.2% (95% CI: 90.7%, 97.9%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
92.9% (95% CI: 89.4%, 96.5%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

CINA-VCF regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240612
  • Samplen=474
  • IndependenceIndependence not established

K240612

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240612. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM non-enhanced or contrast-enhanced CT of the chest and/or abdomen in patients aged 50 years and over, including at least three consecutive measurable vertebrae in the T1-L5 portion of the spine

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K240612: CINA-VCF

  2. Routing

    Source context, not route validation: VCF Image Processing Application can be used with the CINA Platform cleared under K200855 or another compatible medical image communications device. DICOM services connect CT modalities or other DICOM nodes such as routers and PACS, with a Worklist client receiving notifications; exact local versions are not established

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K240612: CINA-VCF

  3. AI processing

    Source context, not route validation: The exact FDA package describes CINA-VCF as running on a standard off-the-shelf server/workstation, with its VCF Image Processing Application integrated, deployed and used with the CINA Platform (K200855) or other compatible medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "CINA-VCF runs on a standard “off the shelf” server/workstation and consists of VCF Image Processing" … "Application, which can be integrated, deployed and used with the CINA Platform (cleared under K200855) or other compatible medical image communications devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K240612: CINA-VCF

  4. Returned objects

    Source context, not route validation: Worklist icon/flag for suspected VCF at T1-L5 and a compressed grayscale unannotated preview marked not for diagnostic use; results are transferred to PACS or a workstation for prioritization and the full original study remains required

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K240612: CINA-VCF

  5. Viewer/worklist/report

    Unresolved route: Worklist icon/flag for suspected VCF at T1-L5 and a compressed grayscale unannotated preview marked not for diagnostic use; results are transferred to PACS or a workstation for prioritization and the full original study remains required

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K240612: CINA-VCF

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes CINA-VCF as running on a standard off-the-shelf server/workstation, with its VCF Image Processing Application integrated, deployed and used with the CINA Platform (K200855) or other compatible medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "CINA-VCF runs on a standard “off the shelf” server/workstation and consists of VCF Image Processing" … "Application, which can be integrated, deployed and used with the CINA Platform (cleared under K200855) or other compatible medical image communications devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
VCF Image Processing Application can be used with the CINA Platform cleared under K200855 or another compatible medical image communications device. DICOM services connect CT modalities or other DICOM nodes such as routers and PACS, with a Worklist client receiving notifications; exact local versions are not established
  • Exact FDA submission
  • Checked 2026-09-08
Security
Avicenna.AI's cybersecurity page states ISO/IEC 27001 certification by SGS, IEC 81001-5-1, TLS 1.2+ in transit, encryption at rest, role-based access with least privilege, and a HIPAA business associate agreement for US customers. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for CINA-VCF; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240612
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Thoracic and lumbar vertebrae T1-L5 within chest and/or abdomen CT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-05-31
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K240612 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K240612: CINA-VCF

    U.S. Food and Drug Administration - Published 2024-05-31 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CINA-VCF model card (K240612)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K240612

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Avicenna.AI Cybersecurity and Data Protection

    Avicenna.AI - Accessed 2026-10-25

    Scope: security

Research history

  1. K240612 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253578

BriefCase-Triage: CARE Multi-Triage CT for Pneumothorax; Pericardial effusion; Large aortic aneurysm; Shoulder fracture or dislocation device

Aidoc Medical, Ltd.

Authorized purpose: BriefCase-Triage CARE Multi-Triage CT analyzes contrast and non-contrast chest, abdomen, or chest/abdomen CT in adults or transitional adolescents aged 18 and older to flag suspected pneumothorax, pericardial effusion, large aortic aneurysm, or shoulder fracture/dislocation for hospital-network workflow triage; notifications and previews are for prioritization, not diagnosis.

Modality
CT/CTA
Anatomy
Chest and abdomen; pneumothorax, pericardial effusion, large aortic aneurysm, and shoulder fracture/dislocation
Decision
2026-02-26
FDA-cleared K252970

BriefCase-Triage: CARE Multi-triage CT Body

Aidoc Medical, Ltd.

Authorized purpose: Adult contrast-enhanced and non-contrast CT triage for 11 chest, abdominal, and pelvic findings: diverticulitis, abdominal-pelvic abscess, appendicitis, intestinal ischemia/pneumatosis, obstructive renal stone, small- and large-bowel obstruction, spleen injury, liver injury, kidney injury, and pelvic fracture.

Modality
CT/CTA
Anatomy
Chest, Abdomen, and Pelvis
Decision
2026-01-07
FDA-cleared K243548

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Workflow triage and notification of suspect cases with three or more acute rib-fracture (RibFx) pathologies in adults or transitional adolescents aged 18 and older.

Modality
CT/CTA
Anatomy
Ribs
Decision
2024-12-11
FDA-cleared K242837

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Triages CT scans including the cervical spine for suspected fracture-compatible linear lucencies.

Modality
CT/CTA
Anatomy
Cervical spine
Decision
2024-10-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history